$1,496,000 of BECTON DICKINSON AND COMPANY lobbying was just disclosed, from Q4 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues related to medical technology regulation Issues related to medical device supply chains and supply chain resiliency Issues related to medical device sterilization Issues related to preventative screenings Issues related to maternal health Issues related to women's health Issues related to diagnostic testing Issues related to corporate taxation Tax incentives for domestic manufacturing Issues related to medical device supply chains and supply chain resiliency Issues related to medical research funding Issues related to medical device sterilization Issues related to medical device supply chain Issues related to international trade Issues related to reimbursement Issues related to CY2026 Home Health and DMEPOS PPS proposed rule"
You can find more data on corporate lobbying on Quiver Quantitative.
BDX Insider Trading Activity
BDX insiders have traded $BDX stock on the open market 12 times in the past 6 months. Of those trades, 1 have been purchases and 11 have been sales.
Here’s a breakdown of recent trading of $BDX stock by insiders over the last 6 months:
- GREGORY HAYES purchased 5,250 shares for an estimated $1,005,742
- CLAIRE FRASER has made 0 purchases and 2 sales selling 1,780 shares for an estimated $337,892.
- MICHAEL DAVID GARRISON (EVP & Pres Med.Essntl&BioPharm) has made 0 purchases and 3 sales selling 1,814 shares for an estimated $336,947.
- MICHAEL FELD (EVP, CRO & Pres. Life Sciences) has made 0 purchases and 5 sales selling 321 shares for an estimated $61,399.
- BERTRAM L SCOTT sold 217 shares for an estimated $38,317
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
BDX Hedge Fund Activity
We have seen 694 institutional investors add shares of BDX stock to their portfolio, and 725 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WELLINGTON MANAGEMENT GROUP LLP added 5,174,944 shares (+9056.3%) to their portfolio in Q3 2025, for an estimated $968,594,268
- PRICE T ROWE ASSOCIATES INC /MD/ removed 4,261,237 shares (-48.0%) from their portfolio in Q3 2025, for an estimated $797,575,729
- FRANKLIN RESOURCES INC added 4,051,718 shares (+150.9%) to their portfolio in Q3 2025, for an estimated $758,360,058
- MANUFACTURERS LIFE INSURANCE COMPANY, THE added 2,258,179 shares (+706.6%) to their portfolio in Q3 2025, for an estimated $422,663,363
- STARBOARD VALUE LP removed 1,411,492 shares (-53.9%) from their portfolio in Q3 2025, for an estimated $264,188,957
- FIRST EAGLE INVESTMENT MANAGEMENT, LLC added 1,208,218 shares (+13.8%) to their portfolio in Q3 2025, for an estimated $226,142,163
- D. E. SHAW & CO., INC. removed 1,084,170 shares (-86.9%) from their portfolio in Q3 2025, for an estimated $202,924,098
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
BDX Price Targets
Multiple analysts have issued price targets for $BDX recently. We have seen 6 analysts offer price targets for $BDX in the last 6 months, with a median target of $208.5.
Here are some recent targets:
- Rick Wise from Stifel set a target price of $215.0 on 01/07/2026
- Travis Steed from B of A Securities set a target price of $207.0 on 01/05/2026
- Shagun Singh from RBC Capital set a target price of $210.0 on 12/17/2025
- Patrick Wood from Morgan Stanley set a target price of $210.0 on 12/02/2025
- Jason Bednar from Piper Sandler set a target price of $190.0 on 11/07/2025
- Lawrence Biegelsen from Wells Fargo set a target price of $184.0 on 08/08/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
